NSK-01105

03/01/2015 - "Collectively, our results suggest a role of NSK-01105 in treatment for human prostate tumors by inhibiting cell proliferation and inducing apoptosis. "
03/01/2015 - "Tumor growth was significantly suppressed by once daily oral 30 mg/kg dose of NSK-01105 with the inhibition rates of 63.82% in LNCaP models and 64.29% in PC-3 models, respectively. "
01/01/2014 - "Collectively, our results suggest a role of NSK-01105 in treatment for human prostate tumors, and one of the potential mechanisms may be attributed to anti-angiogenic activities. "
01/01/2014 - "Tumor volumes were significantly reduced by NSK-01105 at 60 mg/kg/day in both xenograft models. "
03/01/2015 - "Two xenograft tumor models were used to verify the therapeutic effect of NSK-01105 in vivo. "

03/01/2015 - "NSK-01105 exhibited broad-spectrum antitumor activity, particularly in prostate cancer cells. "
03/01/2015 - "The effects of NSK-01105 on proliferation and apoptosis of prostate cancer cells were established by cytotoxicity assays, apoptosis analysis, flow cytometry analysis, and Western blot analysis. "
03/01/2015 - "NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways."